Longevity Biomarkers Testing
TL;DR
Longevity biomarker testing quantifies biological age — the accumulated burden of molecular damage, cellular senescence, and systemic dysregulation — rather than counting chronological years. Five domains are most evidence-backed: epigenetic clocks (GrimAge, measuring DNA methylation patterns trained on mortality outcomes), telomere dynamics (attrition rate predicts mortality better than single length), SASP factors (IL-6, CRP, MCP-1 from senescent cell burden), IGF-1 (U-shaped mortality curve; mid-normal optimal), and Klotho (anti-aging hormone declining with age). These biomarkers are associational, not causally proven as independent drivers of aging — single measurements are noisy; rate-of-change over 12+ months is the actionable signal.
Why It Matters for Vitals
Blood biomarker optimization (ApoB, hs-CRP, insulin, etc.) captures the current cardiometabolic state. Longevity biomarker testing captures the pace of biological aging itself — the rate at which the body’s maintenance systems are declining. Combined, these give Vitals users both the “what is happening now” and the “how fast is the clock ticking” picture. Wearables alone cannot access this layer.
Core Biomarker Reference Table
| Biomarker | What It Measures | Optimal Target | Units |
|---|---|---|---|
| GrimAge | DNA methylation patterns → mortality-trained clock | AgeAccelGrim < 0 (vs chronological) | years |
| Telomere Length | Cellular replicative history | >5th percentile for age; track attrition rate | bp, T/S ratio |
| IL-6 | SASP core cytokine | < 2 pg/mL (low risk) | pg/mL |
| hs-CRP | Systemic inflammation (SASP proxy) | < 1.0 mg/L | mg/L |
| IGF-1 | Growth hormone axis | 100–200 ng/mL in older adults (mid-normal) | ng/mL |
| Klotho | Anti-aging circulating hormone | > 600 pg/mL (relatively protected) | pg/mL |
Key Biomarkers Explained
GrimAge — Epigenetic Clock
GrimAge is a second-generation DNA methylation clock trained on mortality outcomes (not chronological age). It uses methylation at ~1000 CpG sites to estimate biological aging pace, incorporating methylation-based surrogates for plasma proteins (CRP, creatinine, glucose, IGF-1) and a smoking methylation score.
Key metric: AgeAccelGrim (GrimAge acceleration) = residual from regressing GrimAge on chronological age. Each +1 year of AgeAccelGrim → ~6–8% increased hazard of death after adjusting for age, sex, smoking, and BMI.
Interpretation thresholds:
- < −3 years: potentially decelerated aging
- −3 to +3 years: average pace
- +3 to +6 years: moderately accelerated
-
+6 years: significantly accelerated
Limitations: Trained predominantly on European-ancestry cohorts; sensitive to acute inflammation (false positive); requires Illumina Epic 850K array — not available from standard clinical labs.
Telomere Dynamics
Telomeres (TTAGGG repeats) protect chromosome ends; they shorten with each somatic cell division. Telomere length is a proxy for cellular replicative history and accumulated oxidative/inflammatory burden.
Key principle: Rate of attrition predicts mortality better than single-point measurement. Adults losing >40 bp/year have significantly elevated cardiovascular and infectious disease mortality risk.
Measurement methods: qPCR (T/S ratio, relative — less precise) vs Flow-FISH (absolute length in specific leukocyte subsets — more accurate). Longitudinal tracking with same lab/method essential.
SASP Factors
The senescence-associated secretory phenotype (SASP) — IL-6, IL-8, MCP-1, PAI-1, VEGF — reflects senescent cell burden. Circulating SASP factors are non-specific (elevated in any inflammatory condition) but provide a window into the inflammaging burden.
Core clinical markers: IL-6 (< 2 pg/mL = low risk) and hs-CRP (see Blood Biomarker Optimization) serve as practical SASP proxies in clinical practice.
IGF-1
IGF-1 is the primary effector of the growth hormone axis. Evidence is U-shaped: both deficiency (< 100 ng/mL) and excess (> 400 ng/mL) are associated with adverse outcomes. Mid-normal IGF-1 (100–200 ng/mL in older adults) appears optimal for longevity.
Mechanism: IGF-1 activates mTORC1 → protein synthesis but inhibits autophagy. Lower IGF-1 releases the mTOR brake on autophagy (see Autophagy). Resistance exercise causes transient IGF-1 elevation — beneficial as a hormetic signal; chronically elevated IGF-1 loses these benefits.
Klotho
Klotho (named after the Greek goddess who spins life’s thread) is a circulating hormone with anti-inflammatory, anti-oxidative stress, and pro-autophagy effects. Soluble Klotho (sKlotho) declines ~50% between ages 40 and 80. Lower sKlotho is associated with increased cardiovascular events, cognitive decline, and all-cause mortality.
Key interventions: Aerobic exercise, adequate hydration (vasopressin suppresses Klotho), vitamin D optimization (40–60 ng/mL 25-OH D), sodium restriction.
Testing Laboratory Selection
| Biomarker | Recommended Labs | Method | Notes |
|---|---|---|---|
| GrimAge | TruDiagnostic, Elysium Index | Illumina Epic 850K array | Requires blood draw; CLIA-certified labs only |
| Telomere length | SpectraCell, RepeatDx (LabCorp) | qPCR (relative) or Flow-FISH (absolute) | Same-lab longitudinal tracking essential |
| IL-6, hs-CRP | Quest, LabCorp | Clinical immunoassay | Standard clinical chemistry |
| IGF-1 | Quest, LabCorp | Clinical immunoassay | Use age-adjusted reference ranges |
| Klotho | Research / specialty labs | ELISA | Limited commercial availability; high assay variability |
Monitoring Cadence
| Biomarker Domain | Baseline | Low-Risk / Watch | Moderate Risk | High Risk / Elevated |
|---|---|---|---|---|
| GrimAge | Entry | Every 12 months | Every 6 months | Every 3–6 months |
| Telomere (longitudinal) | 2 measurements 12 months apart | Every 12 months | Every 6–12 months | Every 6 months |
| IL-6 + hs-CRP | Baseline panel | Every 12 months | Every 6 months | Every 3–6 months |
| IGF-1 | Baseline (fasting, morning) | Every 12 months | Every 6–12 months | Every 3–6 months |
| Klotho | Baseline | Every 12 months | Every 6–12 months | Every 6 months |
Key principle: minimum 12-month gap between measurements to establish meaningful trend for GrimAge and telomere attrition. Earlier retesting unlikely to detect biologically significant change given measurement error.
Caveats and False Positive Risks
- GrimAge: acute infection elevates it transiently; blood cell composition shifts bias results; ancestry mismatches in reference populations
- Telomere length: qPCR has poor precision; single measurements highly variable; do not over-interpret cross-sectional values
- All biomarkers: causality not established — these are associational, not proven independent drivers of aging
- Composite beats single marker: no single longevity biomarker explains more than a fraction of variance in aging phenotypes; integrate multiple domains
- Psychological risk: learning “biologically older than chronological age” can cause anxiety-driven health behaviors that worsen outcomes
Related Notes
- Blood Biomarker Optimization — the six modifiable cardiometabolic biomarkers (ApoB, hs-CRP, insulin, TG:HDL, HbA1c, iron) — complementary to this note; together they give the full biomarker picture
- Autophagy — autophagy is the cellular mechanism most directly linked to longevity biomarker improvement
- HRV — autonomic function is the wearable-accessible layer closest to longevity biology
- Glycemic Variability — CGM data adds a dimension beyond HbA1c
- Peptides MOC — peptide compounds with known effects on longevity biomarker pathways (Epithalon, Fisetin, PCC1, etc.)